Clinical trials
for patients

The purpose of these studies is to investigate in greater depth issues related to your condition or the study drug. The importance of these additional studies lies in the fact that they will lead to a better understanding of human health and differences in response to drugs and treatments.

The goal of this study is to evaluate whether barzolvolimab (also known as CDX-0159) has long-term effects in keeping chronic spontaneous urticaria (CSU) under control, whether affected individuals can safely stop taking their current oral medications (e.g., antihistamines), and, in cases where CSU has worsened, whether repeating treatment with barzolvolimab can bring it back under control.

The purpose of this study is to evaluate the safety of a new treatment called the FARAFLEX™ Pulsed Field Ablation (PFA) mapping and ablation system and to determine whether it is effective for the treatment of paroxysmal and persistent atrial fibrillation. The ablation that your doctor will perform as part of this study will be similar to the ablation they would perform if you were not participating in the study, except that a different system—one that has already been approved by lo...

The primary objective of this study is to evaluate the safety of the investigational drug, BMS-986340, administered as monotherapy (Part 1A and Part 2A) and in combination with nivolumab (Part 1B and Part 2B). This study will investigate how selected patients with advanced solid tumors tolerate these drugs in order to identify the highest tolerated dose or the most appropriate dose, and to assess any changes in their tumors and overall health after receiving multiple doses of BMS-986340, either ...

The purpose of this study is to test the investigational drug S241656, which is a type of anticancer drug designed to target and block various cancers that have certain types of mutations and other genetic alterations in the tumor that promote its survival and growth.

The primary objective of this study is to evaluate the effects of bempedoic acid/ezetimibe/high-intensity statins on the regression and stabilization of coronary atherosclerotic plaque in patients without serious cardiovascular events

The study aims to determine how effective the study drug is at preventing venous thromboembolism (VTE) and related conditions after total knee arthroplasty, compared with acetylsalicylic acid. VTE involves a blood clot (thrombus) that forms in a vein. Part of the clot can break off and travel through the bloodstream; this is called an embolus. If it reaches the lungs, it can cause a potentially life-threatening pulmonary embolism (PE).

The purpose of this research study is to evaluate the safety and efficacy of an investigational drug called mivelsiran (ALN-APP). This drug has not been approved by the health authorities in your country for use outside this research study. The study drug will be evaluated to determine the effects of mivelsiran in people with early-stage Down syndrome-associated Alzheimer’s disease (DS-AD). The study aims to determine: The effects of mivelsiran on the brain that can be observed using di...

The primary objective of this study is to determine whether survodutide can reduce urinary protein levels in people with overweight who already have protein loss in their urine. This could help reduce the risk of long-term kidney damage.

The purpose of this study is to evaluate the safety and efficacy of each of the three study drugs (Fx, Bv, or Rz) in reducing kidney cell damage, decreasing the amount of protein that leaks into the urine, and improving symptoms, compared with placebo (a dummy treatment containing no active drug).

This study is open to adults with advanced or metastatic solid tumors, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer. Patients may participate if no standard treatment options are available to them and they have a measurable lesion outside the central nervous system. The aim of this study is to determine how well BI 3822971 is tolerated by people with...

This study is designed to collect long-term safety data and provide uninterrupted study treatment to participants with solid tumors who continue to benefit from adagrasib in an eligible clinical trial (parent study).

The aim of this study is to gather further information on how cilta-cel works and its safety in the treatment of patients with multiple myeloma, a type of cancer. The study will include different groups of patients, referred to as cohorts.

This study is designed to help determine whether the study drug pumitamig is effective in treating hepatocellular carcinoma (HCC), a type of liver cancer that is advanced or cannot be removed by surgery (referred to as unresectable).

The aim of this study is to determine the safety and efficacy (how well the study drugs work) of PVEK in combination with venetoclax (VEN) and azacitidine (AZA) in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unable to receive intensive chemotherapy.

This research study evaluates ABP 938 8 mg compared with commercially available aflibercept (Eylea® HD). Its aim is to determine whether the efficacy (how well the study drug injection works), safety, and immunogenicity (the ability to trigger a response in the body to the study drug injection through the development of antibodies, a type of protein) of ABP 938 8 mg are similar to those of aflibercept (Eylea® HD) in the overall study population.

The purpose of this trial is to continue evaluating whether the investigational drug afimkibart, when administered over a longer period, is safe and effective for moderate-to-severe atopic dermatitis, and to determine the long-term effects, both positive and negative, of afimkibart on atopic dermatitis. You are being asked to participate in this trial because you have moderate-to-severe atopic dermatitis, participated in study CS45570, and responded to treatment with afimkibart.

The objective of this study is to determine whether CPV-104 (the study drug) is safe for use in people (safety), how manageable its side effects are (tolerability), the blood concentrations of CPV-104 and factor H (an important protein in the human body involved in the immune system) (pharmacokinetics), and whether CPV-104 triggers an immune response against foreign substances (immunogenicity).